Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.68 |
| ▸ | BLM | P54132 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | THPO | P40225 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295214 | 1.00 | KDM4E (0.68) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| SCHEMBL2298192 | 1.00 | KDM4E (0.68) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL146500 | 0.81 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| SCHEMBL5847942 | 0.81 | KDM4E (0.70) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL17726874 | 0.81 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| SCHEMBL12101294 | 0.81 | KDM4E (0.70) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL2283013 | 0.81 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL28287981 | 0.81 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| SCHEMBL22957651 | 0.80 | GAA (0.56) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| SCHEMBL19399097 | 0.80 | GAA (0.56) | KDM4ETDP1HIF1ABLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718632-B1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2009-04-22 | — | — | EP | claimed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064269-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| EP-2124565-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1457488-B1 | Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008089052-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238709-B2 | Therapeutic carbamates | THERAVANCE, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7112605-B2 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | Research Institute of Materia Medica Chinese Acadamy of Medical Sciences (CN) | 2006-09-26 | — | — | US | disclosed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | RESEARCH INSTITUTE OF MATERIAL MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES; | 2004-02-12 | — | — | US | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029951-A1 | Sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones, preparation method, and medical use thereof | PTGS1, PTGS2, PTGER1 | KDM4E 1122/4885TDP1 3067/4885HIF1A 719/4885 |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | KDM4E 4725/4885TDP1 1476/4885HIF1A 1543/4885 |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | KDM4E 42/4885TDP1 1612/4885HIF1A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.